Business · 22/12/1994
NIH to Grant Exclusive License for Neutralizing Monoclonal Antibodies Against Respiratory Syncytial Virus
The National Institutes of Health (NIH) is considering granting an exclusive worldwide license to SmithKline Beecham Corporation to develop and commercialize neutralizing monoclonal antibodies for treating and preventing Respiratory Syncytial Virus (RSV) infections in humans, with the potential for royalty-bearing revenue.